CTH-001 / Cartherics, Peter MacCallum Cancer Centre - LARVOL DELTA

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma (BioSpace) - "The Peter MacCallum Cancer Centre...and Cartherics Pty Ltd...announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL)....The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. This will initially enrol six patients with refractory CTCL. The primary goal of the clinical trial is to investigate the safety of CTH-001 in this patient population. "

Licensing / partnership • Trial status • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma